Asahi Kasei Acquires Calliditas Therapeutics for $1.1 Billion to Expand in Rare Disease Market

- Asahi Kasei is acquiring Calliditas Therapeutics for $1.1 billion, offering an 83% premium per share.
- The acquisition is part of Asahi Kasei's pharmaceutical growth strategy, particularly in the rare disease market.
- Calliditas' lead product, Tarpeyo, is a treatment for IgA nephropathy, a type of kidney disease.
- Tarpeyo is highly complementary to Asahi Kasei's existing pharmaceutical portfolio.
- The acquisition is expected to accelerate Asahi Kasei's growth as a global healthcare company.